黑料网

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Call Scheduled for Thursday, November 14, 2024 at 5:00 pm ET

LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (鈥淰ivos鈥� or the 鈥淐ompany鈥�) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its third quarter 2024 financial results after market close on Thursday, November 14, 2024.

Vivos鈥� management will conduct a conference call at 5:00 p.m. (Eastern Time) on November 14, 2024 to review the results and provide an overview of Vivos鈥� recent achievements and developments.

To access Vivos鈥� investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the replay is 1196680. The replay will be available until November 29, 2024.

A live webcast of the conference call can be accessed on Vivos鈥� website at . An online archive of the webcast will be available on the Company鈥檚 website for 30 days following the call.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.聽(NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults and children. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical, and cost-effective solution for treating mild to severe OSA in adults and moderate to severe OSA in children. It has proven effective in over 47,000 patients treated worldwide by more than 2,000 trained dentists.

The Vivos Method includes treatment regimens that employ proprietary聽CARE聽appliance therapy and other modalities that alter the size, shape, and position of the jaw and soft tissues that comprise a patient鈥檚 upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults and moderate-to-severe OSA in children ages 6 to 17, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method. Vivos also employs a marketing and distribution model where it collaborates with sleep-treatment providers to offer patients OSA treatment options and help promote sales of its appliances.

For more information, visit .

Cautionary Note Regarding Forward-Looking Statements

This press release, the conference call referred to herein, and statements of the Company鈥檚 management made in connection therewith contain 鈥渇orward-looking statements鈥� (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as 鈥渕ay鈥�, 鈥渟hould鈥�, 鈥渆xpects鈥�, 鈥減rojects,鈥� 鈥渋ntends鈥�, 鈥減lans鈥�, 鈥渂elieves鈥�, 鈥渁nticipates鈥�, 鈥渉opes鈥�, 鈥渆stimates鈥�, 鈥済oal鈥� and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos鈥� control. Actual results (including the actual future impact of the initiatives and corporate achievements described herein on Vivos鈥� future revenues and results of operations and the anticipated benefits of the Company鈥檚 new marketing and distribution model described herein) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos鈥� products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all or maintain its Nasdaq listing and (v) other risk factors described in Vivos鈥� filings with the Securities and Exchange Commission (鈥淪EC鈥�). Vivos鈥� filings can be obtained free of charge on the SEC鈥檚 website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos鈥� expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Vivos Investor Relations and Media Contact:
Bradford Amman, CFO